Company Description

Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid.

It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem.

It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products.

The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.

Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.

Hyperion DeFi, Inc.

Country	United States
Founded	2014
IPO Date	Jan 25, 2018
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Hyunsu Jung

Contact Details

Address: 3090 Nowitzki Way, Suite 300 Dallas, Texas 75219 United States
Phone	833 393 6684
Website	hyperiondefi.com

Stock Details

Ticker Symbol	HYPD
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1682639
CUSIP Number	30234E104
ISIN Number	US30234E2037
Employer ID	47-1178401
SIC Code	2834

Key Executives

Name	Position
Hyunsu Jung	Chief Executive Officer, Chief Investment Officer and Director
David Knox C.F.A.	Chief Financial Officer and Treasurer
Robert Rubenstein	General Counsel and Secretary
Jason Assad	Investor Contact
Alexander Lobo	Investor Contact

Latest SEC Filings

Date	Type	Title
Jun 5, 2026	8-K	Current Report
May 15, 2026	10-Q	Quarterly Report
May 14, 2026	8-K	Current Report
May 6, 2026	8-K	Current Report
May 6, 2026	424B5	Filing
May 5, 2026	ARS	Filing
May 5, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 5, 2026	DEF 14A	Other definitive proxy statements
May 5, 2026	424B5	Filing
Apr 17, 2026	PRE 14A	Other preliminary proxy statements

View All SEC Filings